Entering the 21st century…precisely?

Congress and President Obama are both talking big talk about stepping into the 21st century boldly in terms of healthcare, but what are they really telling us and what will they actually do?
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
So, we recently saw Congress attempt to enter the current century in terms of healthcare when the House Energy and Commerce Committee released a legislative discussion draft as part of its 21st Century Cures initiative. Better late than never? Probably that’s the pessimistic corner of my mind talking; rather than see the glass 85 years full, I see it 15 years empty.
Continue reading below...
A black mosquito is shown on pink human skin against a blurred green backdrop.
InfographicsDiscovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Read More
Granted, there are some good things in that House discussion draft. As business and policy analyst firm Avalere notes, one important aspect for many of you could be a proposal “to expand the Food and Drug Administration’s Patient-Focused Drug Development initiative, including through greater use of patient-reported outcomes as part of the FDA review process. These provisions could be notable in advancing greater patient engagement throughout a product’s life.”
Also, the National Organization for Rare Diseases wrote: “The discussion paper issued by the House Energy and Commerce Committee on January 27 contains a number of ideas on how to advance the development of new medical therapies. A few provisions apply specifically to rare diseases, including adding six months to the patent life of orphan drugs.”
Other notables from draft include talk of better use of surrogate endpoints, expanded access to investigative treatments, streamlined clinical trials, support for continued innovation at federal health agencies and modernization of drug and device regulation.
Continue reading below...
A white, pink, and blue 3D molecular structure of a simple sugar is shown against a light purple background.
WebinarsAdding a little sugar: what glycomics can bring to medicine
Discover how glycoscience is transforming how scientists understand diseases and opening new doors for drug discovery.
Read More
It wasn’t long after this legislative discussion draft emerged that President Barack Obama had his own things to say about healthcare when he gave the State of the Union speech. For his part, rather than have an expansive set of issues and goals—not that such a move is better or worse, mind you; just different—he focused in on personalized medicine when he announced a program called the Precision Medicine Initiative. In his speech before Congress and the rest of the nation, Obama said, “Twenty-first century businesses will rely on American science, technology, research and development. I want the country that eliminated polio and mapped the human genome to lead a new era of medicine—one that delivers the right treatment at the right time."
It’s a good idea, given how important personalized medicine is set to become in healthcare, though Leerink Partners analysts noted, “The President’s FY2016 budget proposal will only include $215 million for the Precision Medicine Initiative, a relatively small number in context of a $30-billion NIH budget, in our view. Most of the money, $130 million, is earmarked for the creation of a one-million-person volunteer cohort.”
Bottom line: I’m of the “wait and see” attitude. Both Congress and Obama are saying important things and both have their eyes—finally—on the current century. But this is also a government that has managed to inadequately fund the National Institutes of Health, the Food and Drug Administration and so many others critical to the health of our nation—for longer than the decade I’ve worked on this magazine.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Fluorescent-style illustration of spherical embryonic stem cells clustered together against a dark background.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes. 
3D illustration of ciliated cells, with cilia shown in blue.
Ultraprecise proteomic analysis reveals new insights into the molecular machinery of cilia.
3D illustration showing a DNA double helix encapsulated in a transparent capsule, surrounded by abstract white and orange protein-like molecular structures against a blue background.
Discover an integrated analytical approach that unites identification, purification, and stability assessment for therapeutic molecules.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue